The use of biomarkers for the diagnosis or prognosis of lung cancer

摘要

A method for identifying diagnosing and monitoring of karzinösem lung tissue in a subject the measurement of the expression of at least a biomarker in a biological sample of the subject, and comparing the expression against a normal value. If a different expression of the at least a biomarker between the biological sample and the normal value is greater than 1,5fach, is the lungs tissue sample cancerous. The at least a biomarker is selected from the group consisting of peroxiredoxin i, peroxiredoxin ii, peroxiredoxin iii, peroxiredoxin iv, peroxiredoxin vi, chaperone, amyloid - p - component (amyloid - p - component), annexin v, dihydropyridines of pyridine midi nose - related 2 protein (dihydropyridines of pyridine midi nose - like 2 protein), glutamate - carboxypeptidase, 2,3 - bisphosphoglycerate - mutase, thymidine - phosphorylase, - 4 - prolyl hydroxylase, selenium - binding protein 1, β - mitochondrial atp synthase h⁺-transported f1 complex (β - mitochondrial atp synthase h⁺ transistor por ting f1 complex), laminin - binding protein, mini chromosome conservation, - faulty protein 5 variant (mini chromogenic some maintenance defined cient protein 5 variant), keratin 9, keratin 10, napsin - a - asparagine - peptidase, m2 - type pyruvate kinase and apolipoprotein a - i.